# Intuity Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intuity-medical

- Industry: Medical Devices & Equipment
- Headquarters: Fremont, US
- Website: www.presspogo.com
- Total disclosed funding: $122M
- Latest round: Series F (Jan 30, 2014)
- Investors on record: 10

## About

Based in the US, Intuity Medical is a healthcare technology company focused on developing innovative solutions for diabetes management and blood glucose monitoring, enhancing patient convenience and accuracy.Intuity Medical, Inc. specializes in diabetes management technology, specifically designed for blood glucose monitoring. Founded in 2002 and headquartered in Fremont, US, the company has undergone significant development in this sector. The latest funding round occurred in May 2019, where the company raised USD 26.27 mn from various investors, bringing the total amount raised to USD 26.27 mn and a current valuation of USD 114.94 mn. The CEO of the company is Emory Anderson, with George Zamanakos also in a key leadership role.Intuity Medical focuses on developing advanced diabetes management systems, including innovative blood glucose monitoring devices that cater to the needs of users seeking greater convenience and accuracy in their health management. Their products are designed to enhance user experience and support effective diabetes care, aligning with industry standards and patient requirements.Intuity Medical generates revenue through the sales of its diabetes management products, particularly its blood glucose monitoring systems. The company operates on a B2B model, engaging with healthcare providers and institutions that require dependable and innovative solutions for diabetes care. Revenue trends are influenced by the growing demand for effective diabetes management tools, reflecting the increasing focus on patient-centric healthcare solutions.Intuity Medical aims to expand its product offerings with new diabetes management devices anticipated to launch in the near future. The company is also looking to penetrate new markets, specifically targeting Europe and select regions in Asia by 2023. Recent funding, raised in May 2019 at USD 26.27 mn, will be utilized to support product development and market expansion initiatives.

## Funding rounds

- Series F, Jan 30, 2014, $5.5M — US Venture Partners, Versant Ventures, Venrock, Accuitive Medical Ventures, Patricia Industries
- Series D, Aug 8, 2012, $12M — US Venture Partners, Versant Ventures, Thomas, McNerney & Partners, Venrock, Accuitive Medical Ventures, Patricia Industries
- Series D, Aug 1, 2011, $12M — US Venture Partners, Versant Ventures, Thomas, McNerney & Partners, Venrock, Accuitive Medical Ventures, Patricia Industries
- Series D, Jan 5, 2010, $64M — US Venture Partners, Versant Ventures, Thomas, McNerney & Partners, Venrock, Patricia Industries, Emergent Medical Ventures
- Series C, Aug 30, 2006, $20M — US Venture Partners, Versant Ventures, Thomas, McNerney & Partners, Patricia Industries, FirstMark Capital
- Series B, Jan 9, 2004, $5M — Versant Ventures, Thomas, McNerney & Partners, SRI International, Pequot Capital Management
- Series A, Jun 26, 2002, $3M — Versant Ventures, Pequot Capital Management

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C, Series D, Series F
- Pequot Capital Management — Series A, Series B
- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series B, Series C, Series D
- SRI International — Series B
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series C, Series D, Series F
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series C, Series D, Series F
- FirstMark Capital (https://capitalatlas.ai/funds/firstmark-capital) — Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series D, Series F
- Emergent Medical Ventures (https://capitalatlas.ai/funds/emergent-medical-ventures) — Series D
- Accuitive Medical Ventures (https://capitalatlas.ai/funds/accuitive-medical-ventures) — Series D, Series F